RLS-0071 Moderated Elevated Myeloperoxidase Level and Activity in an Asymptomatic Subject in Clinical Trial
Jessica M Goss1, Pamela Hair1, Parvathi S Kumar1
1Department of Research and Medical Affairs, ReAlta Life Sciences, Norfolk, VA, USA.
The American Journal of Case Reports
|May 26, 2023
Summary
RLS-0071, a novel peptide, effectively reduced myeloperoxidase (MPO) levels and activity in a healthy volunteer with elevated baseline MPO. This suggests RLS-0071
Area of Science:
- Immunology
- Pharmacology
- Biochemistry
Background:
- RLS-0071 is a dual-targeting peptide designed to regulate inflammation by inhibiting neutrophil effectors like myeloperoxidase (MPO) and neutrophil extracellular trap formation (NETosis).
- Elevated extracellular MPO is implicated in chronic inflammatory conditions such as atherosclerosis.
- Previous studies demonstrated RLS-0071's efficacy in inhibiting MPO function in vitro and in animal models.
